Skip to main content

Table 2 Details of included monotherapy RCTs*

From: Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension

Reference

Badesch 2002

Rubin 2002 (BREATHE-1)

Barst 2006 (STRIDE-2)

Barst 1996

Galie 2005 (SUPER-1)

Baseline therapy

None

None

None

Conventional

None

Add-on therapy

ERA

Placebo

ERA

Placebo

ERA

Placebo

Pr (iv ep)

Conventional

PDE5i

Placebo

Treatment dose

62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks.

62.5 mg bosentan twice daily, increased to either 125 mg or 250 mg twice daily after 4 weeks.

62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks.

mean dose of intravenous epoprostenol 9.2 ng/kg/min

80 mg sildenafil orally 3 times daily

Patients at end of trial

21

11

144

69

60

62

41

40

71

70

Duration

12 weeks

16 weeks

18 weeks

12 weeks

12 weeks

Change 6MWD

70 (23.4)

−6 (50.5)

36 (6.5)

−8 (9.5)

23 (9.3)

−6.5 (9.2)

32 (24.8)

−15 (33)

50 (9)

2 (7)

Baseline 6MWD

360 (18.8)

355 (24.7)

330 (6.2)

344 (9.1)

337 (10.1)

321 (10.8)

316 (18)

272 (23.0)

339 (9.4)

344 (9.4)

Age

52.2

47.4

48.7

47.2

49

53

40

40

48

49

Sex (% male)

0.19

0

0.21

0.22

0.22

0.24

0.24

0.3

0.21

0.19

STATUS

3

3

3.097222

3.057971

2.65

2.693548

3.243902

3.275

2.619718

2.557143

PVR

896

942

1014

880

880

880

1280

1280

918

1051

  1. *ERA are endothelin receptor antagonists, PDE5i are phosphodiesterase 5 inhibitors, Pr are prostacyclin analogues. iv ep is intravenous epoprostenol.